Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

НАЖБП: коморбидность и ассоциированные заболевания

https://doi.org/10.31146/1682-8658-ecg-170-10-57-65

Полный текст:

Аннотация

В настоящее время неалкогольная жировая болезнь печени (НАЖБП) вышла за пределы компетенции врача-гастроэнтеролога и приобрела характер мультидисциплинарной проблемы, которая требует пристального внимания со стороны многих специалистов. Характерной особенностью НАЖБП является многообразие сопутствующих заболеваний и патологических состояний, объединенных общими патофизиологическими механизмами. В данном обзоре обобщены и представлены имеющиеся в современной литературе данные об ассоциации НАЖБП с сердечно-сосудистыми заболеваниями, сахарным диабетом 2 типа, гипотиреозом, синдромом поликистозных яичников, хронической болезнью почек, колоректальным раком, синдромом обструктивного апноэ во сне, остеопорозом, псориазом.

Об авторах

М. А. Ливзан
ФГБОУ ВО «Омский государственный медицинский университет» МЗ РФ
Россия


О. В. Гаус
ФГБОУ ВО «Омский государственный медицинский университет» МЗ РФ
Россия


Н. А. Николаев
ФГБОУ ВО «Омский государственный медицинский университет» МЗ РФ
Россия


Т. С. Кролевец
ФГБОУ ВО «Омский государственный медицинский университет» МЗ РФ
Россия


Список литературы

1. Драпкина О.М., Буеверов А. О. Неалкогольная жировая болезнь печени как мультидисциплинарная патология. М.: Видокс, 2017, 104 с. Drapkina O. M., Bueverov A. O. Nealkogol’naya zhirovaya bolezn’ pecheni kak mul’tidistciplinarnaya patologiya [Non-alcoholic fatty liver disease as a multidisciplinary pathology]. M.: Vidoks, 2017, 104 p.

2. Younossi Z.M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, vol. 64, no. 1, pp. 73–84.

3. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей Российского общества по изучению печени. М.: МЕДпресс-информ, 2015, 48 c. Diagnostika i leceniye nealkogol’noi zhirovoi bolezni pecheni: metodicheskiye recommendatcii dlya vrachey Rossiiskogo obshestva po izucheniyu pecheni [Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors of the Russian society for the study of the liver]. M.: MEDpress-inform, 2015, 48 p.

4. Anstee Q.M., Targher G., Day C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013, no. 10, pp. 330–344.

5. Miele L., Targher G. Understanding the association between developing a fatty liver and subsequent cardio- metabolic complications. Expert Rev Gastroenterol Hepatol, 2015, no. 9, pp. 1243–1245.

6. Ong J.P., Pitts A., Younossi Z. M. Increased overall mortality and liver-related mortality in non- alcoholic fatty liver disease. J Hepatol, 2008, no. 49, pp. 608–612.

7. Angulo P., Kleiner D. E., Dam-Larsen S. et al. Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015, vol. 149, no. 2, pp. 389–397.

8. Ekstedt M., Hagstrom H., Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology, 2014, vol. 61, no. 5, pp. 1547–1554.

9. Kim D., Kim W. R., Kim H. J., Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology, 2013, no. 57, pp. 1357–1365.

10. Драпкина О.М., Яфарова А. А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рациональная фармакотерапия в кардиологии, 2017, vol. 13, no. 5, pp. 645–650. Drapkina O. M., Yafarova A. A. Nealkogol’naya zhirovaya bolezn’ pecheni i serdechno-sosudistii risk: sostoyaniye problemi [Non-alcoholic fatty liver disease and cardiovascular risk: state of the problem]. Ratcional’naya farmakoterapiya v kardiologii – Rational pharmacotherapy in cardiology, 2017, vol. 13, no. 5, pp. 645–650.

11. Гаус О.В., Ахмедов В. А. Тканевой ингибитор матриксных металлопротеиназ-1 как индикатор прогрессирующего течения неалкогольной жировой болезни печени у больных с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2016, Том 7, № 131, c. 32–37. Gaus O. V., Ahmedov V. A. Tissue inhibitor of matrix metalloproteinases-1 as an indicator of the progressive course of non-alcoholic fatty liver disease in patients with metabolic syndrome. Eksperimental’naya i klinicheskaya gastroenterologiya – Experimental and clinical gastroenterology, 2016, vol. 7, no. 131, pp. 32–37.

12. Гаус О.В., Ахмедов В. А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал, 2015, № 1 (124), c. 132–137. Gaus O. V., Ahmedov V. A. Vliyaniye metabolicheskogo sindroma na sostoyaniye parenhimi pecheni i biliarnoi sistemi u patcientov s zhelchnokamennoi bolezn’yu [The effect of metabolic syndrome on the state of the liver parenchyma and biliary system in patients with gallstone disease]. Ural’skii meditcinskii zhurnal – Ural Medical Journal, 2015, no. 1 (124), pp. 132–137.

13. Ливзан М.А., Ахмедов В. А., Кролевец Т. С., Гаус О. В., Черкащенко Н. А. Информативность неинвазивных маркеров фиброза печени у пациентов с неалкогольной жировой болезнью печени. Терапевтический архив, 2016, Т. 88, № 12, c. 62–68. Livzan M. A., Akhmedov V. A., Krolevetc T. S., Gaus O. V., Cherkashenko N. A. Informativnost’ neinvazivnih markerov fi broza pecheni u patcientov s nealkogol’noi zhirovoi bolezn’yu pecheni [Informativeness of non-invasive markers of liver fi brosis in patients with non-alcoholic fatty liver disease]. Terapevticheskiy arhiv – Th erapeutic Archive, 2916, vol. 88, no. 12, pp. 62–68.

14. Ливзан М.А., Колбина М. В., Саламахина О. Ф., и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казанской медицинской школы, 2014, № 1, c. 44–48. Livzan M. A., Kolbina M. V., Salamahina O. F. et al. Gormoni zhirovoi tkani I nealkogol’naya zhirovaya bolezn’ pecheni pri metabolicheskom syndrome [Adipose tissue hormones and non-alcoholic fatty liver disease with metabolic syndrome]. Dnevnik Kazanskoi medicinskoi shkoli – Diary of the Kazan Medical School, 2014, no. 1, pp. 44–48.

15. Ливзан М.А., Лаптева И. В., Миллер Т. С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела // Экспериментальная и клиническая гастроэнтерология, 2014, T. 8, № 108, с. 27–33. Livzan M. A., Lapteva I. V., Miller T. S. The role of leptin and leptin resistance in the formation of non-alcoholic fatty liver disease in individuals with obesity and overweight. Eksperimental’naya i klinicheskaya gastroenterologiya – Experimental and clinical gastroenterology, 2014, vol. 8, no. 108, pp 27–33.

16. Akabame S., Hamaguchi M., Tomiyasu K. et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64- detector multislice computed tomography (MSCT). Circ J, 2008, no. 72, pp. 618–625. 17. Kim D., Choi S. Y., Park E. H. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcifi cation. Hepatology, 2012, no. 56, pp. 605–613 18. VanWagner L.B., Ning H., Lewis C. E. et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: Th e Coronary Artery Risk Development in Young Adults Study. Atherosclerosis, 2014, no. 235, pp. 599–605.

17. Fraser A., Harris R., Sattar N. et al. Gammaglutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s Heart and Health Study and Meta- Analysis. Arterioscler Th romb Vasc Biol, 2007, no. 27, pp. 2729–2735.

18. VanWagner L.B., Wilcox J. E., Colangelo L. A. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology, 2015, vol. 62, no. 3, pp. 773–783.

19. Wannamethee S.G., Whincup P. H., Shaper A. G. et al. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Th romb Vasc Biol, 2012, no. 32, pp. 830–835.

20. Ballestri S., Lonardo A., Bonapace S. et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol, 2014, vol. 20, pp. 1724–1745.

21. Portillo-Sanchez P., Bril F. M., Maximos M. et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab, 2015, vol. 100, pp. 2231–2238.

22. Koehler E.M., Plompen E. P., Schouten J. N. et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: Rotterdam study. Hepatology, 2016, vol. 63, no. 1, pp. 138–147.

23. Arulanandan A., Ang B., Bettencourt R. et al. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol, 2015, no. 13, pp. 1513–1520.

24. Seppala-Lindroos A., Vehkavaara S., Hakkinen A. M. et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab, 2002, no. 87, pp. 3023–3028.

25. Williamson R.M., Price J. F., Glancy S. et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care, 2011, no. 34, pp. 1139–1144.

26. Rinella M. E. Nonalcoholic fatty liver disease: a systematic review. Jama, 2015, no. 313, pp. 2263–2273.

27. Ryu S., Chang Y., Jung H. S. et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol, 2015, vol. 63, no. 5, pp. 1229–1237.

28. Targher G., Bertolini L., Chonchol M. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia, 2010, no. 53, pp. 1341–1348.

29. Adams L.A., Waters O. R., Knuiman M. W. et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol, 2009, no. 104, pp. 861–867.

30. Pagadala M.R., Zein C. O., Dasarathy S. et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci, 2012, no. 57, pp. 528–534.

31. Chung G.E., Kim D., Kim W. et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol, 2012, no. 57, pp. 150–156.

32. Eshraghian A., Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol, 2014, no. 20, pp. 8102–8109.

33. Kelley C. E., Brown A. J., Diehl A. M., Setji T. L. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol, 2014, no. 20, pp. 14172–14184.

34. Ramezani-Binabaj M., Motalebi M., Karimi-Sari H. et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon, 2014, no. 14, e23235 p.

35. Targher G., Rossini M., Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine, 2015, vol. 51, no. 2, pp. 211–221.

36. Targher G., Bertolini L., Rodella S. et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol, 2010, no. 5, pp. 2166–2171.

37. Musso G., Cassader M., Cohney S. et al. Emerging Liver- Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med, 2015, no. 21, pp. 645–662.

38. Cheungpasitporn W., Thongprayoon C., O’Corragain O. A. et al. Associations of sugar-sweetened and artifi cially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton), 2014, no. 19, pp. 791–797.

39. Pacifi co L., Bonci E., Andreoli G. M. et al. Th e impact of nonalcoholic fatty liver disease on renal function in children with overweight/ obesity. Int J Mol Sci, 2016, no. 17, 1218 p.

40. Musso G., Gambino R., Tabibian J. H. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med, 2014, no. 11, 1001680 p.

41. Baguet J.P., Barone-Rochette G., Tamisier R. et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol, 2012, no. 9, pp. 679–688.

42. Aron-Wisnewsky.J, Minville C., Tordjman J. et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol, 2012, no. 56, pp. 225–233.

43. Corey K.E., Misdraji J., Gelrud L. et al. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci, 2015, no. 60, pp. 2523–2538.

44. Musso G., Cassader M., Olivetti C. et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Reviews, 2013, no. 14, pp. 417–431.

45. Sundaram S.S., Sokol R. J., Capocelli K. E. et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr, 2014, no. 164, pp. 699–706.

46. Targher G., Lonardo A., Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest, 2015, no. 38, pp. 817–825.

47. Li M., Xu Y., Xu M. et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab, 2012, no. 97, pp. 2033–2038.

48. Ferlay J., Shin H. R., Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer, 2010, no. 127, pp. 2893–2917.

49. Jinjuvadia R., Lohia P., Jinjuvadia C. et al. Th e association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol, 2013, no. 47, pp. 33–44.

50. Ganzetti G., Campanati A., Offi dani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol, 2015, no. 7, pp. 315–326.

51. Van der Voort E. A., Koehler E. M., Dowlatshahi E. A. et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol, 2014, no. 70, pp. 517–524.

52. Miele L., Vallone S., Cefalo C. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol, 2009, no. 51, pp. 778–786.

53. Roberts K.K., Cochet A. E., Lamb P. B. et al. Th e prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Th er, 2015, no. 41, pp. 293–300.

54. Gisondi P., Targher G., Zoppini G., Girolomoni G. Nonalcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol, 2009, no. 51, pp. 758–764.


Для цитирования:


Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;1(10):57-65. https://doi.org/10.31146/1682-8658-ecg-170-10-57-65

For citation:


Livzan M.A., Gaus O.V., Nikolaev N.A., Krolevetz T.S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57-65. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-170-10-57-65

Просмотров: 55


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)